论文部分内容阅读
目的:观察罗格列酮对2型糖尿病合并急性冠脉综合征患者血清转化生长因子-β1(TGF-β1)及白细胞介素-1β(IL-1β)的影响。方法:116例2型糖尿病合并急性冠脉综合征患者,随机分为罗格列酮治疗组(n=58)和常规治疗组(n=58)。检测两组患者治疗前后空腹血糖、血脂及血清TGF-β1、IL-1β的变化。结果:治疗前两组患者空腹血糖、血脂及血清TGF-β1、IL-1β的水平无显著差异(P>0.05);治疗4月后,两组患者空腹血糖、血脂无显著差异,血清IL-1β较治疗前下降(P<0.01),罗格列酮组较常规治疗组下降明显,两组间差异显著(P<0.05);治疗后血清TGF-β1较治疗前上升(P<0.05),罗格列酮组与常规治疗组比较,差异显著(P<0.05)。结论:罗格列酮能调控糖尿病合并急性冠脉综合征患者炎症介质和抗炎因子的分泌,可能具有改善动脉粥样硬化的作用。
Objective: To observe the effect of rosiglitazone on serum levels of transforming growth factor-β1 (TGF-β1) and interleukin-1β (IL-1β) in type 2 diabetic patients with acute coronary syndrome. Methods: A total of 116 patients with type 2 diabetes mellitus complicated with acute coronary syndrome were randomly divided into rosiglitazone group (n = 58) and conventional treatment group (n = 58). The changes of fasting blood glucose, blood lipid, serum TGF-β1 and IL-1β in two groups before and after treatment were detected. Results: There was no significant difference in fasting blood glucose, serum lipids and serum levels of TGF-β1 and IL-1β between the two groups before treatment (P> 0.05). After 4 months of treatment, there was no significant difference in fasting blood glucose and blood lipid between the two groups. Serum IL- (P <0.01). The level of TGF-β1 in rosiglitazone group was significantly lower than that in the conventional treatment group (P <0.05) Rosiglitazone group compared with the conventional treatment group, the difference was significant (P <0.05). CONCLUSION: Rosiglitazone can modulate the secretion of inflammatory mediators and anti-inflammatory cytokines in patients with diabetes mellitus complicated with acute coronary syndrome and may have the effect of improving atherosclerosis.